Positive results from multiple in vivo studies have shown the impact of sphingosine kinase-2 (SPHK2) inhibition in various models of metabolic disease.

RedHill Biopharma announced the positive study results, which show the effect of opaganib on weight gain and glucose tolerance in a high fat diet (HFD) model.

The company says the data support the potential clinical use of opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.

The studies showed the benefit of opaganib therapy in suppression of HFD-induced body weight gain, loss of glucose tolerance and fat deposition.

Additionally, opaganib treatment reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders.

“Sphingolipid metabolism is a key pathway in many diseases, including obesity, but has not been adequately examined as a therapeutic target for human therapy,” said Dr Mark Levitt, Chief Scientific Officer at RedHill. “Opaganib, which acts as a sphingosine competitor, is the first clinical drug to target three key enzymes in this pathway.”

The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk’s Ozempic and Wegovy (semaglutide), and Eli Lilly’s Trulicity (dulaglutide) and Mounjaro (tirzepatide), and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim’s Jardiance (Empagliflozin).

The range of indications for opaganib

Opaganib has anticancer, anti-inflammatory and antiviral activity, targeting multiple potential diseases, including obesity-related syndromes, prostate cancer and cholangiocarcinoma, gastrointestinal acute radiation syndrome, Sulfur Mustard exposure, Covid-19, Ebola and other viruses.

It’s host-directed action is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis, and disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolising enzymes in human cells (SPHK2, DES1 and GCS).

The drug delivered a statistically significant increase in survival time when given at 150mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.

In prespecified analyses of Phase II/III clinical data in hospitalised patients with moderate to severe Covid-19, oral opaganib demonstrated improved viral RNA clearance, faster time to recovery and significant mortality reduction in key patient subpopulations versus placebo on top of standard of care.

It has also received orphan drug designation from the FDA for the treatment of cholangiocarcinoma and has undergone studies in advanced cholangiocarcinoma (Phase IIa) and prostate cancer.

Diana Spencer, Senior Digital Content Editor, DDW